Sophiris Bio, Inc.
SPHS
SPHS was delisted on the 11th of March, 2020.
35 hedge funds and large institutions have $6.73M invested in Sophiris Bio, Inc. in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
17% more funds holding
Funds holding: 30 → 35 (+5)
4% more capital invested
Capital invested by funds: $6.45M → $6.73M (+$277K)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
45% less call options, than puts
Call options by funds: $412K | Put options by funds: $752K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$484K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$126K |
| 3 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$67.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$31.5K |
| 5 |
Bank of New York Mellon
New York
|
+$28.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$250K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$55.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$43.3K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$31.8K |
| 5 |
Barclays
London,
United Kingdom
|
-$30.7K |
SPHS Hedge Fund Activity: Q3 2018 in Review
35 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q3 2018, worth a combined $6.73M — up 4.3% from $6.45M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SPHS positions and 1 closed out — a net gain of 5 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Hikari Power, opening a new position worth an estimated $484K. The largest seller was JP Morgan Chase, cutting an estimated $250K.
- 35 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q3 2018, up from 30 in Q2 2018.
- Funds reported $6.73M of Sophiris Bio, Inc. stock for Q3 2018, up 4.3% quarter-over-quarter.
- 6 funds opened new Sophiris Bio, Inc. positions in Q3 2018 and 1 closed out, a net change of +5 holders.
- The largest Sophiris Bio, Inc. buyer in Q3 2018 was Hikari Power, an estimated $484K added.
- The largest Sophiris Bio, Inc. seller in Q3 2018 was JP Morgan Chase, an estimated $250K sold.
Based on aggregated 13F filings for Q3 2018.